1. Introduction {#s0005}
===============

Metastatic involvement of bone is one of the common complications in advanced cancer. Almost all of patients with myeloma, 65--75% of patients with breast or prostate cancer, and 30--40% of patients with lung cancer develop skeletal metastases [@bib1]. Nearly 50% of patients with bone metastases develop one or more complications collectively termed skeletal-related events (SREs) (i.e., radiation to bone, pathological fracture, spinal cord compression, surgery to bone) [@bib2], [@bib3]. Incidence of SRE has been used as the composite primary endpoint in the trials conducted to reduce skeletal complications among patients with bony metastases since 2002 [@bib4], [@bib5]. SREs reduced performance status, quality of life (QOL) and reduced survival. SREs also increase patients\' risk of hospitalization and the duration of hospital stays. They are estimated to cost 1.9 billion dollars every year in the United States, with the cost to treat a single SRE episode per patient varying from 6973 to 11979 USD [@bib6], [@bib7].

Bisphosphonates (BP) have played a central part in the prevention of skeletal complications. In particular, zoledronic acid (ZA) demonstrated the broadest range of clinical benefits. Evidence showed that ZA can significantly reduce the bone pain and the risk of SREs for patients with bone metastases secondary to a wide range of solid tumors [@bib8], [@bib9], [@bib10]. Growing evidence indicates that denosumab is a promising new treatment option for patients with bone metastases. Denosumab is a fully humanized monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANK-L) which plays a central role in osteoclast formation, differentiation, and survival [@bib11], [@bib12], [@bib13]. Thus, denosumab can inhibit bone destruction through inhibiting the function of RANK-L. Two phase II studies showed that denosumab reduced levels of bone turnover markers consistently, regardless of tumor types or prior BP exposure [@bib14], [@bib15]. In addition, recent studies found that denosumab was non-inferior or even superior to ZA in delaying or preventing SREs in patients with bone metastasis [@bib16], [@bib17].

In the present study, we systematically reviewed and assessed the evidence to compare the efficacy of denosumab with that of ZA in reducing morbidity of SREs for patients with bone metastases.

2. Material and methods {#s0010}
=======================

2.1. Search strategies {#s0015}
----------------------

We searched for both non-English and English articles in PUBMED, EMBASE, Cochrane Library, Web of Science with Conference Proceedings, Elsevier and China National Knowledge Infrastructure (CNKI) databases till August 2017. The following key words were searched as terms: skeletal-related event, SRE, denosumab, bisphosphonates, zoledronic acid, ZA, bone metastases, cancer. There was no restriction on time period, population, language. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications. The computerized search was supplemented by a manual search of the bibliographies of all retrieved articles by two independent reviewers.

2.2. Inclusion/exclusion criteria of literature {#s0020}
-----------------------------------------------

The studies were included if they satisfied the following criteria: (1) RCTs and case series; (2) Information on the SRE results of denosumab versus ZA in patients with bone metastases; (3) The papers had to provide the size of the samples, distribution of the incidence of SRE or other information that can help us estimate an odds ratio (OR) and 95% confidence interval (95% CI).

The studies were excluded if one of the following existed: (1) The review articles and studies that contained overlapping data; (2) Not offering the source of cases and controls or other essential information; (3) If more than one study from the same group occurred, we only recruited the most recent or complete study.

2.3. Statistical analysis {#s0025}
-------------------------

The following information was extracted from each eligible study by two investigators independently with the standard protocol: the name of first author, year of publication, country of origin, study setting, study population, the sample size of denosumab group and ZA group, usage of denosumab and ZA, SREs (radiation to bone, pathological fracture, spinal cord compression, surgery to bone). To ensure the accuracy of the extracted information, two investigators checked the data extraction results and reached consensus on all of the data extracted. If different results were generated, they would check the data again and have a discussion to come to an agreement. The results were reviewed by a third investigator and disagreement was resolved by discussion.

OR and a 95% CI were used for presenting the statistical results for dichotomous outcomes. Weighted mean difference (WMD) and a 95% CI were employed for presenting the statistical results for continuous outcomes. Mantel-Haenszel analysis was utilized for dichotomous variables, and inverse variance method was used for continuous variables [@bib18]. The statistical significance was set at *P* \< 0.05.

The difference was considered to be statistically significant if a *P* value was less than 0.10 and was also quantitatively assessed by using the value of I-square (I^2^ \< 25%, no heterogeneity; I^2^ between 25% and 50%, moderate heterogeneity; and I^2^ \> 50%, high heterogeneity) [@bib19]. If I^2^ \< 50% or *P* \> 0.10, it shows that the studies were homogeneous or slightly heterogeneous, and we will use the fixed-effects model to combine the effect size. If I^2^ \> 50% or *P* \< 0.10, indicating that the studies were moderately or highly heterogeneous, and we will employ the random-effects model to combine the effect size [@bib20]. Statistical calculations were performed by using the computer program Review Manager (RevMan) Version 5.3 (Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

3. Results {#s0030}
==========

3.1. Search results and features of studies included {#s0035}
----------------------------------------------------

The initial search was independently executed by two reviewers, and 35 articles were preliminarily selected based on the research criteria. After screening by title and abstract in accordance with inclusion/exclusion criteria, 17 studies were excluded. After a thorough discussion between the 2 reviewers, three articles were found to be related to this study. The detailed steps of the literature search are shown in [Fig. 1](#f0005){ref-type="fig"}. This review covered 3 studies [@bib21], [@bib22], [@bib23] from a total of 4050 participants. The name of first author, year of publication, country of origin, study setting, study population, the sample size of denosumab group and ZA group, usage of denosumab and ZA, and outcome parameter (SRE types) of each study were listed in [Table 1](#t0005){ref-type="table"}. The information of SRE types and the sample size in denosumab group and ZA group of each study are given in [Table 2](#t0010){ref-type="table"}.Fig. 1Flow diagram of the literature search.Fig. 1Table 1Characteristics of included studies in this meta-analysis.Table 1First authorYearCountryDesignStudy populationSample (Denosumab/ZA)TreatmentAssessment of outcomes (SRE types)Size(Denosumab/ZA)Outcome parameterHWEPopulationHWEMartin 212012SpainRCTBreast cancer2046 (1026/1020)Denosumab 120 mg IhRadiation to bone, Pathological fracture, Spinal cord compression, Surgery to boneQ4W;Smith 222014AmericaRCTProstate cancer1901 (950/951)ZA 4 mg IV Q4WRadiation to bone, Pathological fracture, Spinal cord compression, Surgery to boneDenosumab 120 mg Ih Q4W;Hibiki 232017JapanCase seriesNSCLC103 (52/51)Q4W;Radiation to bone, Pathological fracture, Spinal cord compression, Surgery to boneZA 4 mg IV Q4WNA[^2]Table 2Patients^,^ SREs of the trials included in the meta-analysis.Table 2First authorRadiation to bonePathological fractureSpinal cord compressionSurgery to boneDenosumab (n/N)ZA (n/N)Denosumab (n/N)ZA (n/N)Denosumab (n/N)ZA (n/N)Denosumab (n/N)ZA (n/N)Martin 2182/102695/1020215/1026235/102010/102610/102010/102610/1020Smith 22177/950203/951137/950143/95126/95036/9511/9504/951Hibiki 23NANA2/521/510/524/51NANA26/95036/9511/9504/951[^3]

3.2. Result of meta-analysis {#s0040}
----------------------------

The detailed steps of our literature search are shown in [Fig. 1](#f0005){ref-type="fig"}. In brief, we identified 4 RCTs that met the inclusion criteria for this meta-analysis.

The pooled analysis showed that denosumab could significantly reduce SREs as compared with ZA, series SREs (OR = 0.84; 95% CI, 0.74--0.95, I^2^ = 0%, P = 0.008) ([Fig. 2](#f0010){ref-type="fig"}) in patients with bone metastases. The meta-analysis showed the similar results in spinal cord compression SRE (OR = 0.84; 95% CI, 0.70--1.01, I^2^ = 0%, P = 0.07), surgery to bone SRE (OR = 0.92; 95% CI, 0.78--1.08, I^2^ = 0%, P = 0.28), radiation to bone SRE (OR = 0.72; 95% CI, 0.46--1.10, I^2^ = 11%, P = 0.13) and pathological fracture SRE (OR = 0.78; 95% CI, 0.35--1.73, I^2^ = 25%, P = 0.54) separately ([Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}), and there were no significant difference between denosumab and ZA in patients with bone metastases.Fig. 2Forest plot: summary OR of denosumab compared with ZA for series SREs.Fig. 2Fig. 3Forest plot: summary OR of denosumab compared with ZA for radiation to bone SRE.Fig. 3Fig. 4Forest plot: summary OR of denosumab compared with ZA for pathological fracture.Fig. 4Fig. 5Forest plot: summary OR of denosumab compared with ZA for spinal cord compression.Fig. 5Fig. 6Forest plot: summary OR of denosumab compared with ZA for surgery to bone SRE.Fig. 6

3.3. Publication bias {#s0045}
---------------------

We did not draw funnel plot to demonstrate publication bias, because the number of the included studies was comparatively small.

4. Discussion {#s0050}
=============

This meta-analysis indicates that denosumab is associated with a decreased risk of SREs for patients with bone metastases when compared with ZA. However, the pooled analysis found no difference in clinical outcome of spinal cord compression SRE, surgery to bone SRE, radiation to bone SRE and pathological fracture SRE.

Although both denosumab and ZA inhibit bone resorption, the working mechanism is different. It is hypothesized that a vicious cycle of bone metastases is established between bone destruction and tumor growth [@bib24], [@bib25]. Tumor cells metastasized to the bone produce growth factors that induce osteoblasts to secrete RANK-L. Binding of RANK-L to its receptor RANK stimulates osteoclast formation, differentiation, and bone resorption. In turn, the increased bone resorption provides the tumor cells with growth factors from the bone matrix that stimulate tumor growth [@bib26]. Denosumab disrupts the vicious cycle in the bone microenvironment by binding to RANK-L and inhibits its function, however, it is suggested that ZA interrupts this vicious cycle by preventing the prenylation of small GTPase proteins essential for osteoclast function and survival [@bib27].

Denosumab is a cost-effective treatment option for the prevention of SREs in patients with advanced solid tumors and bone metastases compared to ZA. The overall value of denosumab is based on superior efficacy, favorable safety, and more efficient administration [@bib28]. The safety profile for ZA and denosumab is similar but subcutaneous administration of denosumab offers advantages over intravenous administration with no need for renal monitoring. Denosumab is associated with fewer acute phase reactions, but has a higher incidence of hypocalcemia [@bib29].

We performed a thorough search of the literature to capture all relevant information. In addition, the quality of studies included in our meta-analysis was satisfactory. They are all randomized, double-blind controlled trials. Nevertheless, our meta-analysis has several limitations. The main potential limitation is the very small number of clinical trials available for inclusion in the meta-analysis. Similarly, the evidence comparing the efficacy of denosumab and ZA on the incidence of SRE among the subgroups like lung cancers, colon cancer, and multiple myeloma could not be provided because of insufficient information. However, large, multicenter, and randomized trials are still needed to assess longer-term safety and efficacy of denosumab. Further research should also determine whether, in addition to patients naive to BP treatment, patients who did not respond well to ZA would benefit from denosumab therapy.
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